Amgen and J&J have billions of dollars at stake in the battle to convince CMS to change its coverage proposal for EPO in cancer patients. Win or lose, their efforts will be a valuable case study for any other manufacturer that fi nds itself facing an adverse reimbursement policy.
By Michael McCaughan
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
